

# Decelerated chirality interconversion of an optically inactive $\text{3}_{10}$ -helical peptide by metal chelation

Naoki Ousaka,<sup>\*a</sup> Norihiko Tani,<sup>b</sup> Ryo Sekiya,<sup>b</sup> and Reiko Kuroda<sup>\*ab</sup>

## Electronic supplementary information

### 1. Measurements

$^1\text{H}$  NMR spectra were recorded on a JEOL model JNM-A500 (500 MHz) spectrometer, where chemical shifts were determined with respect to tetramethylsilane as internal reference. MALDI-TOF MS spectrum was recorded on an Applied Biosystems model Voyager-DE mass spectrometer using 1,8,9-anthracenetriol matrix and NaI salt for sample preparation. ESI mass spectra were recorded on a Mariner™ ESI-TOF Biospectrometry Workstation.


### 2. Materials

Synthetic procedure of peptide **1** has been already reported.<sup>7d</sup> Pyridine-3-carboxylic acid (Kanto Chemical Co., INC.) was used without further purification. Coupling reagents such as 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC: Kokusan Chemical Co. Ltd.) and 1-hydroxy-1H-benzotriazole, monohydrate (HOBr: Wako Pure Chemical Industries Ltd) were used without further purification. Pd(en)(ONO<sub>2</sub>)<sub>2</sub> was purchased from Wako Pure Chemical Industries Ltd., and used without further purification. Pt(en)(ONO<sub>2</sub>)<sub>2</sub> was prepared according to the literature method.<sup>81</sup> N,N-diisopropylethylamine (DIEA: Sigma-Aldrich INC.) and 4N solution of HCl in 1,4-dioxane (Kokusan Chemical Co. Ltd.) were used without further purification. N,N-dimethylformamide (DMF) was obtained as dehydrated-grade reagents from Wako Pure Chemical Industries Ltd.


### 3. Synthesis of 2

2: To a solution of pyridine-3-carboxylic acid (38 mg, 0.31 mmol), HOBr (57 mg, 0.37 mmol), EDC (59 mg, 0.31 mmol), and Cbz-[Aib<sub>2</sub>-Api(HCl)]<sub>2</sub>-Aib<sub>2</sub>-OMe (0.089 mmol) [obtained by treatment of **1** (100 mg, 0.089 mmol) with 4N solution of HCl in 1,4-dioxane] in DMF (1 mL) at 0 °C, DIEA (71 µL, 0.44 mmol) was added. The reaction mixture was stirred at 0 °C for 3 h, and at room temperature for 4 days. Then, the solution was evaporated to dryness under reduced pressure. The residue was purified by a column chromatography on silica gel (chloroform/methanol = 9/1), and size-exclusion column chromatography in DMF. Then, recrystallization from ethyl acetate/hexane provided peptide **2** (74 mg, 73 %) as a white solid.  $^1\text{H}$  NMR (500 MHz, CD<sub>3</sub>CN, 20 °C): δ = 8.62 (bs, 1H), 8.57 (m, 3H), 7.87 (bs, 1H), 7.72 (m, 2H), 7.62 (s+s, 2H), 7.59 (bs, 1H), 7.53 (s, 1H), 7.43 (s, 1H), 7.41-7.31 (m+m, 7H), 7.18 (s, 1H), 6.50 (s, 1H), 5.13 (s, 2H), 4.45 (bs, 1H), 4.34 (bs, 1H), 3.58 (s, 3H), 3.55 (bs, 1H), 3.46 (bs, 1H), 3.31+3.10 (bs+bs, 2H), 2.85 (bs, 1H), 2.20-1.89 (closely overlapping with H<sub>2</sub>O and solvent), 1.44+1.41+1.39+1.39 (s+s+s+s, 36H, partially overlapping). MALDI-TOF-MS: [M+Na]<sup>+</sup> (calcd. 1161.57): found. 1160.89.


**4. Additional Spectroscopic Data and Energy-Minimized Structure of 2.**




**Fig. S1** MALDI-TOF mass spectrum of **2**.




**Fig. S2** Side (left) and top (right) views of right-handed **2** [type I (a), III (b), and IV (c)] energy-minimized by the semi-empirical MO calculation (PM 6 method<sup>14</sup>).<sup>17</sup> Hydrogen atoms are omitted for clarity. The schematic representations indicate the side-chain orientations of amide carbonyl.




**Fig. S3**  $^1\text{H}$  NMR monitored titration of **2** with **5** in  $\text{CD}_3\text{CN}$  at 20 °C. Initial concentration of **2** is set to 4.8 mM (2.7 mg/500  $\mu\text{L}$ ). A desired amount of the  $\text{CD}_3\text{CN}$  solution of **2** (3.1 mg/400  $\mu\text{L}$ ) was directly added to the NMR tube. After titration of **5**, final peptide concentration is 4.0 mM.




**Fig. S4** Variable temperature <sup>1</sup>H NMR spectra of **4** in CD<sub>3</sub>CN/DMSO-*d*<sub>6</sub> (100/1; v/v); [4] = 3.5 mM. The complex **4** was obtained by the following procedure; a 1:1 mixture of **2** (4.0 mg, 3.5  $\mu$ mol) and [Pt(en)(ONO<sub>2</sub>)<sub>2</sub>] (1.3 mg, 3.5  $\mu$ mol) in CD<sub>3</sub>CN/DMSO-*d*<sub>6</sub> (1.0 mL/10  $\mu$ L; v/v) was heated at 55–60 °C for overnight.




**Fig. S5** Solvent dependence on NH chemical shifts of peptides **4** in CD<sub>3</sub>CN/DMSO-*d*<sub>6</sub> mixture at 20 °C in 500 MHz <sup>1</sup>H NMR spectra.



**Fig. S6** Wide-range variable temperature  $^1\text{H}$  NMR spectra of **2** (left) and **3** (right) in CD<sub>3</sub>CN. These spectra correspond to Fig. 3.



**Fig. S7**  $^1\text{H}$ - $^1\text{H}$  COSY (500 MHz) spectra of **3** (left) and **4** (right) in CD<sub>3</sub>CN/DMSO-*d*<sub>6</sub> (DMSO-*d*<sub>6</sub> = 7 vol%) at 20 °C.



**Fig. S8** Expanded TOCSY (500 MHz) spectrum of **2** (left) in  $\text{CD}_3\text{CN}$  and **3** (right) in  $\text{CDCN}_3/\text{DMSO}-d_6$  ( $\text{DMSO}-d_6 = 4 \text{ vol\%}$ ) for **3** at room temperature;  $[\mathbf{2}] = 6.0 \text{ mM}$ ,  $[\mathbf{3}] = 9.6 \text{ mM}$ .

## 5. Reference

(S1) F. Basolo, J. C. Bailar and B. R. Tarr, *J. Am. Chem. Soc.*, 1950, **72**, 2433.